This is not the most recent version of the article. View current version (18 AUG 2016)

Intervention Review

You have free access to this content

Hormonal contraceptives for contraception in overweight or obese women

  1. Laureen M Lopez1,*,
  2. David A Grimes2,
  3. Mario Chen3,
  4. Conrad Otterness4,
  5. Carolyn Westhoff5,
  6. Alison Edelman6,
  7. Frans M Helmerhorst7

Editorial Group: Cochrane Fertility Regulation Group

Published Online: 30 APR 2013

Assessed as up-to-date: 4 FEB 2013

DOI: 10.1002/14651858.CD008452.pub3


How to Cite

Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A, Helmerhorst FM. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD008452. DOI: 10.1002/14651858.CD008452.pub3.

Author Information

  1. 1

    FHI 360, Clinical Sciences, Research Triangle Park, North Carolina, USA

  2. 2

    University of North Carolina, School of Medicine, Obstetrics and Gynecology, Chapel Hill, North Carolina, USA

  3. 3

    FHI 360, Division of Biostatistics, Research Triangle Park, North Carolina, USA

  4. 4

    FHI 360, Program Sciences, Research Triangle Park, North Carolina, USA

  5. 5

    Columbia University, Dept of Obstetrics and Gynecology, New York, New York, USA

  6. 6

    Oregon Health & Science University, Dept. of Obstetrics and Gynecology, Portland, Oregon, USA

  7. 7

    Leiden University Medical Center, Department of Gynaecology, Division of Reproductive Medicine and Dept. of Clinical Epidemiology, Leiden, Netherlands

*Laureen M Lopez, Clinical Sciences, FHI 360, P.O. Box 13950, Research Triangle Park, North Carolina, 27709, USA. llopez@fhi360.org.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

This is not the most recent version of the article. View current version (18 AUG 2016)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Burkman 2009 {published and unpublished data}
  • Burkman RT, Fisher AC, Wan GJ, Barnowski CE, LaGuardia KD. Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. Contraception 2009;79(6):424-7.
  • Hampton RM, Short M, Bieber E, Bouchard C, Ayotte N, et al. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20. Contraception 2001;63(6):289-95.
  • Hampton RM, Zhang HF, Barnowski C, Wan GJ. Bleeding patterns with monophasic and triphasic low-dose ethinyl estradiol combined oral contraceptives. Contraception 2008;77(6):415-9.
  • Zhang H, LaGuardia K, Creanga D. Higher body weight and body mass index are not associated with reduced efficacy in Ortho Tri-Cyclen Lo users (abstract). Obstetrics and Gynecology 2006;107(4 Suppl):50S.
Grubb 1995 {published data only}
Gu 1995 {published data only}
Jain 2004 {published data only}
Sivin 1997a {published data only}
Westhoff 2012a {published data only}
  • Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception 2010;81(1):41-8.
  • Westhoff CL, Hait HI, Reape KZ. Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive. Contraception. 2011/11/10 2012; Vol. 85, issue 3:235-9.
WHO 1990 {published data only}
  • World Health Organization, Task Force on Long-Acting Systemic Agents for Fertility Regulation. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. I. Contraceptive efficacy and side effects. Contraception 1990;41(2):105-24.
  • World Health Organization, Task Force on Long-Acting Systemic Agents for Fertility Regulation. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. II. Expulsions and removals. Contraception 1990;41(2):125-41.
  • World Health Organization, Task Force on Long-Acting Systemic Agents for Fertility Regulation. Microdose intravaginal levonorgestrel contraception: a multicentre clinical trial. III. The relationship between pregnancy rate and body weight. World Health Organization. Contraception 1990;41(2):143-50.
Xu 2012 {published data only}
  • Secura GM, Allsworth JE, Madden T, Mullersman JL, Peipert JF. The Contraceptive CHOICE Project: reducing barriers to long-acting reversible contraception. American Journal of Obstetrics and Gynecology. 2010/06/15 2010; Vol. 203, issue 2:115 e1-7.
  • Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstetrics and Gynecology. 2012/06/09 2012; Vol. 120, issue 1:21-6.
Zieman 2002 {published data only}
  • Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. Journal of the American Medical Association 2001;285(18):2347-54.
  • Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW. Efficacy and safety of a transdermal contraceptive system. Obstetrics and Gynecology 2001;98(5 Pt 1):799-805.
  • Urdl W, Apter D, Alperstein A, Koll P, Schonian S, Bringer J, et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. European Journal of Obstetrics & Gynecology and Reproductive Biology 2005;121(2):202-10.
  • Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertility and Sterility 2002;77(2 Suppl 2):S13-8.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Banerjee 1984 {published data only}
  • Banerjee SK, Baweja R, Bhatt RV, Chatterjee A, Choudhury SD, Coyaji B, et al. Comparative evaluation of contraceptive efficacy of norethisterone oenanthate (200 mg) injectable contraceptive given every two or three monthly. Indian Council of Medical Research Task Force on Hormonal Contraception. Contraception 1984, issue 6:561-74.
Berenson 2011 {published data only}
  • Berenson AB, van den Berg P, Williams KJ, Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. Obstet Gynecol. 2010/12/22 2011; Vol. 117, issue 1:41-7.
Casey 2011 {published data only}
  • Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception. 2011/04/12 2011; Vol. 83, issue 5:426-30. [1879-0518: (Electronic)]
Cirkel 1990 {published data only}
  • Cirkel U, Schneider HPG. [Incidence of side effects caused by a three-stage preparation administered to 10,034 women] [[Nebenwirkungsinzidenz eines Dreistufenpräparates unter der Anwendung bei 10.034 Frauen]]. Geburtshilfe und Frauenheilkunde 1991;50(12):969-73.
Du 2000 {published data only}
  • Du MK, Chow LP, Zheng HM, Chen CH. A 10-year follow-up study of contraceptive Norplant implants. International Journal of Gynaecology & Obstetrics. 2000/03/04 2000; Vol. 68, issue 3:249-56.
  • Du MK, Zheng HM, Chen HC, Chow LP. Study of Norplant implants in Shanghai: three-year experience. International Journal of Gynaecology & Obstetrics. 1990/12/01 1990; Vol. 33, issue 4:345-57.
Glasier 2011 {published data only}
  • Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception. 2011/09/17 2011; Vol. 84, issue 4:363-7.
Graesslin 2008 {published data only}
  • Graesslin O, Korver T. The contraceptive efficacy of Implanon®: a review of clinical trials and marketing experience. European Journal of Contraception and Reproductive Health Care 2008;13(Suppl 1):4-12.
Moreau 2012 {published data only}
  • Moreau C, Trussell J. Results from pooled Phase III studies of ulipristal acetate for emergency contraception. Contraception. 2012/07/10 2012.
Mornar 2012 {published data only}
  • Mornar S, Chan L-N, Mistretta S, Neustadt A, Martins S, Gilliam M. Pharmacokinetics of the etonogestrel contraceptive implant in obese women. American Journal of Obstetrics and Gynecology August 2012; Vol. 207, issue 110:e1-6. [: NCT00724438]
  • Neustadt A, Gilliam M. Pharmacokinetics of Implanon in obese women. http://clinicaltrials.gov/ct2/show/NCT00724438 (accessed 15 Sep 2009). [: NCT00724438]
Sivin 1988 {published data only}
Sivin 1997b {published data only}
  • Sivin I, Viegas O, Campodonico I, Diaz S, Pavez M, Wan L, et al. Clinical performance of a new two-rod levonorgestrel contraceptive implant: a three-year randomized study with Norplant implants as controls. Contraception 1997;55(2):73-80.
Sivin 2000 {published data only}
  • Sivin I, Mishell DR, Diaz S, Biswas A, Alvarez F, Darney P, et al. Prolonged effectiveness of Norplant(R) capsule implants: a 7-year study. Contraception 2000, issue 3:187-94.
Weisberg 1999 {published data only}

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Kaunitz 2012 {published data only (unpublished sought but not used)}
  • Kaunitz A, Archer DF, Foegh M. Increased compliance with a low-dose combination contraceptive patch (AG200-15) compared with a low-dose combination oral contraceptive (COC) in a Phase 3 clinical trial (abstract). Contraception 2012;86(2):178.
  • Kaunitz A, Foegh M, Mishell D. Increased compliance independent of patient demographics with a low-dose combination contraceptive patch (AG200-15) compared with a low-dose combination oral contraceptive in a Phase 3 clinical trial (abstract). Contraception 2012;86(3):314.
  • Kaunitz AM, Mishell DR, Foegh M. Comparative Phase 3 study of AG200-15, a low-dose estrogen and levonorgestrel contraceptive patch. http://www.agiletherapeutics.com/Clinical_support.html (accessed 26 Sep 2012).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
Balshem 2011
Brunner Huber 2006
  • Brunner Huber LR, Hogue CJ, Stein AD, Drews C, Zieman M. Body mass index and risk for oral contraceptive failure: a case-cohort study in South Carolina. Annals of Epidemiology 2006;16(8):637-43.
Brunner 2005
Brunner Huber 2007
CDC 2012
  • Centers for Disease Control and Prevention. Defining Overweight and Obesity. http://www.cdc.gov/obesity/adult/defining.html (accessed 19 Dec 2012).
CONSORT 2009
  • CONSORT group. CONSORT: Transparent reporting of trials. http://www.consort-statement.org/ (accessed 10 Oct 2012).
Dinger 2009
  • Dinger JC, Cronin M, Mohner S, Schellschmidt I, Minh TD, Westhoff C. Oral contraceptive effectiveness according to body mass index, weight, age, and other factors. American Journal of Obstetrics and Gynecology 2009;201(3):263.e1-9.
Dinger 2011
  • Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen. Obstetrics and Gynecology. 2011/01/11 2011; Vol. 117, issue 1:33-40.
Edelman 2009a
Edelman 2009b
  • Edelman AB, Carlson NE, Cherala G, Munar MY, Stouffer RL, Cameron JL, et al. Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity. Contraception 2009;80(2):119-27.
Flegal 2012
Gallo 2011
Grimes 2005a
Grimes 2010a
Grimes 2010b
Guyatt 2011
  • Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology 2011;64(4):383-94.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. John Wiley & Sons, Ltd, (accessed 26 Mar 2012).
Holt 2002
Holt 2005
Lopez 2012
Ogden 2007
  • Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States— no change since 2003–2004. NCHS data brief no 1. Hyattsville (MD): National Center for Health Statistics, 2007.
Prentice 2006
Schulz 2002
Segall-Gutierrez 2010
  • Segall-Gutierrez P, Taylor D, Liu X, Stanczyk F, Azen S, Mishell DR. Follicular development and ovulation in extremely obese women receiving depo-medroxyprogesterone acetate subcutaneously. Contraception 2010;81(6):487-95.
Sivin 2001
  • Sivin I, Wan L, Ranta S, Alvarez F, Brache V, Mishell DR, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception 2001;64(1):43-9.
Strauss 2005
  • Strauss SE, Richardson WS, Glasziou P, Haynes RB. Evidence-based Medicine: How to Practice and Teach EBM. Third Edition. New York: Churchill Livingstone, 2005.
Trussell 2009
UN 2011
  • United Nations, Department of Economic and Social Affairs, Population Division. World Contraceptive Use 2011. http://www.un.org/esa/population/publications/contraceptive2011/contraceptive2011.htm (accessed 02 May 2012).
Vessey 2001
Wells 2011
  • GA Wells, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 29 Nov 2011).
Westhoff 2005
  • Westhoff C. Higher body weight does not affect NuvaRing's efficacy (abstract). Obstetrics and Gynecology 2005;105(4 Suppl):56S.
Westhoff 2008
Westhoff 2009
  • Westhoff C, Torgal A, Mayeda ER, Lerner J, Paik M. Ovarian suppression during oral contraceptive use in normal-weight and obese women. Contraception 2009;80(2):210.
Westhoff 2012b
  • Westhoff CL, Torgal AH, Mayeda ER, Petrie K, Thomas T, Dragoman M, et al. Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women. American Journal of Obstetrics and Gynecology 2012;207(1):39.e1-6.
Westhoff 2012c
WHO 2012
  • World Health Organization. Obesity. http://www.euro.who.int/en/what-we-do/health-topics/noncommunicable-diseases/obesity (accessed 27 Dec 2012).